Boiron SA
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties compr… Read more
Boiron SA (BOI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.076x
Based on the latest financial reports, Boiron SA (BOI) has a cash flow conversion efficiency ratio of 0.076x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€28.13 Million) by net assets (€369.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Boiron SA - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Boiron SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Boiron SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boiron SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Naintech Co. Ltd.
KQ:267320
|
0.068x |
|
Rivco Australia Ltd
AU:RIV
|
-0.042x |
|
Lang Inc
TW:6165
|
0.065x |
|
CELTIC PLC LS 001
F:CCP
|
N/A |
|
Singatron Enterprise Co Ltd
TWO:6126
|
0.017x |
|
Fiera Milano S.p.A.
LSE:0EGH
|
-0.673x |
|
Paiho Shih Holdings Corp
TW:8404
|
0.025x |
|
Fonar Corporation
NASDAQ:FONR
|
0.001x |
Annual Cash Flow Conversion Efficiency for Boiron SA (2001–2024)
The table below shows the annual cash flow conversion efficiency of Boiron SA from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €378.18 Million | €39.53 Million | 0.105x | -10.04% |
| 2023-12-31 | €391.50 Million | €45.49 Million | 0.116x | +10.35% |
| 2022-12-31 | €557.35 Million | €58.69 Million | 0.105x | +68.07% |
| 2021-12-31 | €531.77 Million | €33.32 Million | 0.063x | -53.27% |
| 2020-12-31 | €509.17 Million | €68.27 Million | 0.134x | +33.25% |
| 2019-12-31 | €505.46 Million | €50.86 Million | 0.101x | -41.95% |
| 2018-12-31 | €486.04 Million | €84.25 Million | 0.173x | -14.36% |
| 2017-12-31 | €517.49 Million | €104.75 Million | 0.202x | -13.69% |
| 2016-12-31 | €469.60 Million | €110.13 Million | 0.235x | -5.42% |
| 2015-12-31 | €416.04 Million | €103.16 Million | 0.248x | -2.04% |
| 2014-12-31 | €379.88 Million | €96.16 Million | 0.253x | -7.32% |
| 2013-12-31 | €391.86 Million | €107.02 Million | 0.273x | +9.17% |
| 2012-12-31 | €354.16 Million | €88.59 Million | 0.250x | +56.78% |
| 2011-12-31 | €368.65 Million | €58.82 Million | 0.160x | +6.24% |
| 2010-12-31 | €343.84 Million | €51.64 Million | 0.150x | -41.34% |
| 2009-12-31 | €313.28 Million | €80.20 Million | 0.256x | +6.15% |
| 2008-12-31 | €271.49 Million | €65.48 Million | 0.241x | +7.40% |
| 2007-12-31 | €249.94 Million | €56.13 Million | 0.225x | +33.97% |
| 2006-12-31 | €230.09 Million | €38.57 Million | 0.168x | -7.68% |
| 2005-12-31 | €229.88 Million | €41.74 Million | 0.182x | -23.95% |
| 2004-12-31 | €144.09 Million | €34.40 Million | 0.239x | -2.79% |
| 2003-12-31 | €149.53 Million | €36.73 Million | 0.246x | -4.17% |
| 2002-12-31 | €134.47 Million | €34.46 Million | 0.256x | -8.21% |
| 2001-12-31 | €119.17 Million | €33.27 Million | 0.279x | -- |